Eric Joseph
Stock Analyst at JP Morgan
(2.13)
# 3,004
Out of 5,105 analysts
123
Total ratings
40%
Success rate
-3.17%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TGTX TG Therapeutics | Maintains: Overweight | $46 → $49 | $31.35 | +56.30% | 5 | Nov 3, 2025 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $48 → $46 | $27.36 | +68.13% | 4 | Oct 9, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $89.68 | -28.64% | 4 | Jun 3, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $44 → $7 | $3.39 | +106.49% | 4 | May 28, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $4.10 | - | 5 | May 20, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $6.57 | +6.54% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $75.64 | -11.42% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.38 | - | 4 | Apr 25, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Neutral | n/a | $1.23 | - | 4 | Feb 10, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $31 → $30 | $19.07 | +57.32% | 7 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $14 | $6.69 | +109.27% | 5 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $71 | $78.92 | -10.04% | 6 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $25.44 | +49.37% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $6.49 | +254.39% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $16.56 | +2.66% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $8.03 | +161.52% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $14.73 | -32.11% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.41 | +963.83% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $2.47 | +142.91% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $10 | $4.33 | +130.95% | 2 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $16.31 | -32.56% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $34.46 | +190.19% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $0.56 | +796.54% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.15 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $45.00 | -75.56% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $24.69 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $6.95 | +1,626.62% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $13.30 | +2,156.49% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $10.15 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $1.61 | +459.01% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.66 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $2.79 | +1,405.38% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $3.58 | +263.13% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.45 | +2,344.44% | 3 | Nov 14, 2018 |
TG Therapeutics
Nov 3, 2025
Maintains: Overweight
Price Target: $46 → $49
Current: $31.35
Upside: +56.30%
Beam Therapeutics
Oct 9, 2025
Maintains: Overweight
Price Target: $48 → $46
Current: $27.36
Upside: +68.13%
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $89.68
Upside: -28.64%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Neutral
Price Target: $44 → $7
Current: $3.39
Upside: +106.49%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.10
Upside: -
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $6.57
Upside: +6.54%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $75.64
Upside: -11.42%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.38
Upside: -
Pliant Therapeutics
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.23
Upside: -
Nurix Therapeutics
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $19.07
Upside: +57.32%
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $6.69
Upside: +109.27%
Dec 3, 2024
Maintains: Overweight
Price Target: $63 → $71
Current: $78.92
Upside: -10.04%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $25.44
Upside: +49.37%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $6.49
Upside: +254.39%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $16.56
Upside: +2.66%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $8.03
Upside: +161.52%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $14.73
Upside: -32.11%
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.41
Upside: +963.83%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $2.47
Upside: +142.91%
Nov 13, 2023
Maintains: Neutral
Price Target: $11 → $10
Current: $4.33
Upside: +130.95%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $16.31
Upside: -32.56%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $34.46
Upside: +190.19%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $0.56
Upside: +796.54%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.15
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $45.00
Upside: -75.56%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $24.69
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $6.95
Upside: +1,626.62%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $13.30
Upside: +2,156.49%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $10.15
Upside: -
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $1.61
Upside: +459.01%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.66
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $2.79
Upside: +1,405.38%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $3.58
Upside: +263.13%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.45
Upside: +2,344.44%